Senologie - Zeitschrift für Mammadiagnostik und -therapie 2022; 19(02): e18
DOI: 10.1055/s-0042-1748384
Abstracts | DGS

Adjuvant abemaciclib combined with endocrine therapy (ET): updated results from monarchE

Authors

  • N. Harbeck

    1   Brustzentrum der Universität München (LMU), München, Deutschland

  • J. O’Shaughnessy

    2   Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, Vereinigte Staaten,

  • P. Rastogi

    3   University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, Vereinigte Staaten,

  • M. Toi

    4   Kyoto University Hospital, Kyoto, Japan

  • R. Hegg

    5   Clin. Pesq.e Centro São Paulo, São Paulo, Brasilien,

  • J. Sohn

    6   Yonsei Cancer Center, Seoul, Korea, Republik

  • V. Guarneri

    7   University of Padova, Istituto Oncologico Veneto IOV IRCCS, Padova, Italien,

  • J. Cortes

    8   International Breast Cancer Center (IBCC), and Vall d’Hebron Institute of Oncology, Madrid & Barcelona, Spanien,

  • E. Hamilton

    9   Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, Vereinigte Staaten,

  • R. Wei

    10   Eli Lilly and Company, Indianapolis, IN, Vereinigte Staaten,

  • A. Shahir

    10   Eli Lilly and Company, Indianapolis, IN, Vereinigte Staaten,

  • B. San Antonio

    10   Eli Lilly and Company, Indianapolis, IN, Vereinigte Staaten,

  • S. Nabinger

    10   Eli Lilly and Company, Indianapolis, IN, Vereinigte Staaten,

  • S. Tolaney

    11   Dana-Farber Cancer Institute, Boston, MA, Vereinigte Staaten,

  • M. Martin

    12   Hospital General Universitario Gregorio Marañon, Madrid, Spanien,

  • S. Johnston

    13   Royal Marsden NHS Foundation Trust, London, Vereinigtes Königreich
Further Information
Also available at
 
 

Objective Adjuvant abemaciclib (CDK4&6 inhibitor)+ET provides significant and clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in HR+, HER2-, node+, high-risk early breast cancer (EBC). Updated results with 27-month median follow-up are presented.

Materials/Methods Patients were randomized (1:1) to receive ET for up to 10 years +/- abemaciclib for 2 years. Patients had ≥4+ axillary lymph nodes (ALN), or 1-3+ ALN and either grade-3 disease or tumor≥5 cm (Cohort-1), or 1-3+ ALN and centrally tested Ki-67 ≥20% (Cohort-2). For intent-to-treat (ITT) (cohort 1+2) and Ki-67 populations, hazard ratio (HR) was estimated using Cox proportional hazard model (data cutoff=1-April-2021). Exploratory analyses estimated piecewise HR within each year in ITT.

Results With 90% patients having completed/discontinued 2-year study treatment period, IDFS and DRFS benefit was maintained (HR=0.696; 95%CI=0.588,0.823; HR=0.687; 95%CI=0.571,0.826). At 3 years, absolute improvement in IDFS/DRFS rates=5.4/4.2%. Abemaciclib benefit deepened during treatment period (estimated IDFS/DRFS piecewise HR at year 0-1=0.795/0.732, year 1-2=0.681/0.675) and persisted after treatment period (2+ year IDFS/DRFS piecewise HR=0.596/0.692). IDFS rates at 3 years in Cohort-1 control arm (79.0%/87.2% in Ki-67 High/Low) confirmed prognostic value of Ki-67; abemaciclib benefit was consistent regardless of Ki-67 index (HR=0.626/0.704 in Ki-67 High/Low). Adverse event profile was similar to prior analysis.

Summary Benefit of adjuvant abemaciclib+ET is strengthened within and beyond the 2-year treatment period in HR+, HER2-, node+, high-risk EBC. High Ki-67 was prognostic, but not predictive of abemaciclib benefit. Safety profile remains acceptable for patients with EBC treated with curative intent.


Publication History

Article published online:
21 June 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany